Table 1.
Clinical characteristics of patients with bone metastatic prostate cancer in relation to relative levels of miRNA-23c and -4328.
| Characteristics | miRNA-23c (n = 67) | miRNA-4328 (n = 67) | |
|---|---|---|---|
| Age diagnosis (yrs) | 69 (63; 76) | 0.17 (0.072; 0.48) | 0.10 (0.034; 0.30) |
| Age metastasis surgery (yrs) | 73 (67; 79) | - | - |
| Serum PSA diagnosis (µg/L) | 110 (47; 750) | - | - |
| Serum PSA metastasis surgery (µg/L) | 290 (86; 980) | - | - |
| Follow-up after androgen-deprivation therapy (months) | 43 (25; 73) | - | - |
| Follow-up after metastasis surgery (months) | 10 (3.0; 31) | - | - |
| Gleason score at diagnosis: | |||
| 7 | 18 (27%) | 0.17 (0.061; 0.37) | 0.086 (0.032; 0.34) |
| 8–10 | 28 (42%) | 0.19 (0.078; 0.85) | 0.17 (0.044; 0.35) |
| Not available | 21 (31%) | NA | NA |
| Castration therapy a: | |||
| None (hormone-naïve) | 15 (22%) | 0.13 (0.060; 0.17) | 0.032 (0.025; 0.052) |
| Short-term b | 4 (6.0%) | 0.42 (0.24: 0.46) | 0.27 (0.13; 5.1) * |
| CRPC | 48 (72%) | 0.21 (0.075; 0.71) * | 0.13 (0.044; 0.31) * |
Continuous variables given as median (25th; 75th percentiles). Categorical variables are given as numbers (%). Relative miRNA levels were assessed by reverse transcription and quantitative polymerase chain reaction and expressed in relation to levels in benign prostate tissue, as described in Materials and Methods. * p < 0.05 when compared to hormone-naïve (Mann–Whitney U-test). a Castration therapies given prior to collection of metastasis tissue samples included surgical ablation, LHRH/GnRH agonist therapy or bicalutamide treatment. b Castration therapy for 1 day to 3 days before metastasis tissue sampling. NA, not analyzed.